文献速递流行病学与生物统计新药、器械与细胞基因治疗研发

DESCAR-T登记研究中CAR T细胞治疗后发生的T细胞恶性肿瘤

T cell malignancies after CAR T cell therapy in the DESCAR-T registry.
PubMed 文献 · Nat Med · 2025-01-08

该研究分析法国DESCAR-T登记数据库自2018年7月1日起接受CAR T细胞治疗的全部儿童和成人血液恶性肿瘤患者,共纳入3,066例。中位随访后仅1例(0.03%)发生T细胞恶性肿瘤,为接受替沙基奥仑赛治疗弥漫大B细胞淋巴瘤3年后诊断的原发性皮肤CD30+ T细胞淋巴增殖性疾病(间变性淋巴瘤激酶阴性),并发现CAR克隆整合至抑癌基因PLAAT4。结论认为CAR T细胞治疗后T细胞恶性肿瘤风险极低。

要点

  • DESCAR-T登记共纳入3,066例接受CAR T细胞治疗的血液恶性肿瘤患者。
  • 中位随访后仅1例(0.03%)发生T细胞恶性肿瘤,为皮肤CD30+ T细胞淋巴增殖性疾病。
  • 该例在替沙基奥仑赛治疗弥漫大B细胞淋巴瘤3年后诊断,伴CAR克隆整合至PLAAT4。

核心结论

  • 研究结论认为CAR T细胞治疗后T细胞恶性肿瘤的风险极低。
  • 该例继发性T细胞恶性肿瘤的发生可能与CAR T细胞治疗的使用有关。

研究设计与样本

  • 分析DESCAR-T登记数据库,涵盖自2018年7月1日起在法国接受CAR T细胞治疗的全部儿童和成人血液恶性肿瘤患者。
  • 共纳入3,066例,其中B细胞淋巴瘤2,536例、B细胞急性淋巴细胞白血病162例、多发性骨髓瘤368例。
  • 1,680例(54.8%)接受阿基仑赛,205例(6.7%)接受brexucabtagene autoleucel,44例(1.4%)接受lisocabtagene maraleucel,769例(25.1%)接受替沙基奥仑赛。
  • 多发性骨髓瘤患者全部接受idecabtagene vicleucel,无一例接受ciltacabtagene autoleucel。
  • B细胞淋巴瘤中位随访12.7个月,B细胞急性淋巴细胞白血病17.7个月,多发性骨髓瘤6.3个月。

主要发现

  • 仅1例(0.03%)患者在CAR T细胞输注后发生T细胞恶性肿瘤。
  • 该例在接受替沙基奥仑赛治疗弥漫大B细胞淋巴瘤3年后诊断为原发性皮肤CD30+ T细胞淋巴增殖性疾病(间变性淋巴瘤激酶阴性)。
  • 该例与CAR克隆整合至抑癌基因PLAAT4(磷脂酶A和酰基转移酶4)相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The risk of T cell malignancies after chimeric antigen receptor (CAR) T cell therapy is a concern, although the true incidence remains unclear. Here we analyzed the DESCAR-T registry database, encompassing all pediatric and adult patients with hematologic malignancies who received CAR T cell therapy in France since 1 July 2018. Of the 3,066 patients included (2,536 B cell lymphoma, 162 B cell acute lymphoblastic leukemia (ALL) and 368 multiple myeloma), 1,680 (54.8%) received axicabtagene ciloleucel, 205 (6.7%) brexucabtagene autoleucel, 44 (1.4%) lisocabtagene maraleucel and 769 (25.1%) tisagenlecleucel. All multiple myeloma patients received idecabtagene vicleucel, with none receiving ciltacabtagene autoleucel. After a median follow-up of 12.7 months for B cell lymphoma, 17.7 months for B cell ALL and 6.3 months for multiple myeloma, only one (0.03%) patient developed a T cell malignancy after CAR T infusion. Specifically, the patient was diagnosed with a primary cutaneous CD30+ T cell lymphoproliferative disorder (anaplastic lymphoma kinase-negative) 3 years after receiving tisagenlecleucel therapy for diffuse large B cell lymphoma. This was associated with the integration of a CAR clone into the tumor suppressor gene PLAAT4 (phospholipase A and acyltransferase 4). Thus, the development of this secondary T cell malignancy might be linked to the use of CAR T cell therapy. In conclusion, our findings indicate a very low risk of T cell malignancy after CAR T cell therapy.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Dulery R, Guiraud V, Choquet S, et al. T cell malignancies after CAR T cell therapy in the DESCAR-T registry. Nat Med. 2025. PMID: 39779930. doi:10.1038/s41591-024-03458-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。